Naofumi Hara, Eiki Ichihara, Hirohisa Kano, Chihiro Ando, Ayako Morita, Tatsuya Nishi, Sachi Okawa, Takamasa Nakasuka, Atsuko Hirabae, Masaya Abe, et al. CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer. Translational lung cancer research. 2023. 12. 10. 2098-2112
Chihiro Ando, Eiki Ichihara, Tatsuya Nishi, Ayako Morita, Naofumi Hara, Kenji Takada, Takamasa Nakasuka, Hiromi Watanabe, Hirohisa Kano, Kazuya Nishii, et al. Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer. Cancer science. 2023
Toshio Kubo, Eiki Ichihara, Daijiro Harada, Koji Inoue, Keiichi Fujiwara, Sinobu Hosokawa, Daizo Kishino, Haruyuki Kawai, Nobuaki Ochi, Naohiro Oda, et al. Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancer. Respiratory investigation. 2023. 61. 5. 643-650
Ken Sato, Nagio Takigawa, Toshio Kubo, Hideki Katayama, Daizo Kishino, Toshiaki Okada, Akiko Hisamoto, Junko Mimoto, Nobuaki Ochi, Tadashi Yoshino, et al. Effect of a Cyclooxygenase-2 Inhibitor in Combination with (-)-Epigallocatechin Gallate or Polyphenon E on Cisplatin-Induced Lung Tumorigenesis in A/J Mice. Acta medica Okayama. 2023. 77. 1. 65-70
Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
(ESMO Asia Annual Meeting 2019)
American Society of Clinical Oncology
, American Association for Cancer Research
, 日本緩和医療学会
, 日本癌治療学会
, 日本臨床腫瘍学会
, 日本呼吸器内視鏡学会
, 日本肺癌学会
, 日本呼吸器学会
, 日本内科学会